Hansa Biopharma: Negative anti-GBM Phase III Readout - Redeye
Redeye comments on the topline data from the phase III study of imlifidase in anti-GBM disease. There was no difference between the treatment and control arm. We remove the anti-GBM indication from our valuation.
ANNONS
Redeye comments on the topline data from the phase III study of imlifidase in anti-GBM disease. There was no difference between the treatment and control arm. We remove the anti-GBM indication from our valuation.
